
This is the draft version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: https://openaccess.city.ac.uk/id/eprint/17388/

Link to published version: https://doi.org/10.1016/j.aucc.2017.02.003

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
BLOOD FLOW RATE AND CIRCUIT LIFE IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT): A RANDOMISED CONTROLLED TRIAL (RCT).

Nigel Fealy* 1, 2, 3, Leanne Aitken2, 4, 5, Eugene du Toit6, Ian Baldwin1, 3, Serigne Lo7
1Department of Intensive Care, Austin Health, Melbourne, 2School of Nursing and Midwifery, Griffith University, Brisbane, 3School of Nursing and Midwifery, Deakin University, Melbourne, 4Princess Alexandra Hospital, Brisbane, Australia, 5City University London, London, United Kingdom, 6School of Medical Science, Griffith University, Gold Coast, 7Melanoma Institute of Australia, Sydney, Australia

There is minimal evidence to inform blood flow rate (BFR) during CRRT. We aimed to assess the effect of BFR on circuit life during CRRT.

A prospective RCT was conducted over one year in our tertiary ICU. Adult patients with acute kidney injury were randomised to either 150 or 250 mls/min. Circuit and patient data were collected until each circuit clotted or ceased electively. Duration data for clotted circuits are presented as median (Interquartile range) and compared using the log-rank test; p was set at <0.05. Circuit clotting data were analysed for repeated events using a hazards ratio (HR).

One hundred patients were randomised with 96 completing the study (150 mls/min-49; 250 mls/min-47) with 462 circuits; 245:150 mls/min and 217:250 mls/min. Median circuit life for 1st circuit (clotted) was similar for both groups (150 mls/min: 9.1 [5.5, 26] hrs vs. 10 [4.2, 17] hrs; p=0.37). Second and third circuits were also similar. 150 mls/min: 14 [8.5,21] hrs vs. 13.8 [8.5, 16.7] hrs; p=0.44. 150 mls/min: 17 [10.5, 28.5] hrs vs. 16 [12, 21.5] hrs; p=0.52 respectively. CRRT using 250 mls/min was not more likely to cause clotting compared to 150 mls/min (HR, 1.06 [0.63, 1.78]; p=0.36, variance of the random effect, 1.096 [0.23]). There were no differences in likelihood of clotting for: BMI, weight, vascular access type, length or site, mode of CRRT, INR or platelet count. CRRT with no use of anticoagulation was more likely to cause clotting compared to use of heparin or heparin/protamine (HR 1.61, [1.17, 2.21], p=0.002). Longer APTT was associated with a lower likelihood of circuit clotting (HR 0.98,[0.97, 0.99], p=0.002). Clotting was more probable in males (HR 1.64 [0.87, 3.08] p=0.02).

Blood flow rate did not effect clotting during CRRT. Males and use of anticoagulation and APTT were more likely to affect circuit survival.

Disclosure of Interest: None Declared